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ABSTRACT OF DISSERTATION
NEUROPSYCHOLOGICAL CORRELATES OF STRIATAL DOPAMINERGIC
DYSFUNCTION IN PARKINSON’S DISEASE
Parkinson’s disease (PD) is a common neurodegenerative disorder associated with
dysfunction of the basal ganglia, which contributes to a range of motor, cognitive, and
affective symptoms. Striatal dopaminergic deficits are one of the core pathological
mechanisms thought to contribute to the extra-motor (i.e., cognitive and affective)
symptoms in early PD. The present study investigated the relationship between striatal
dopaminergic integrity and cognition in 21 patients with PD and 21 age and education
matched controls. Each individual underwent dopamine transporter (DaT) imaging with
single photon emission computed tomography (SPECT) (i.e., DaTscan) and standardized
neuropsychological testing. Strong positive associations were found between DaT
availability in the striatum and verbal memory (r = .52-.61) and problem solving/setshifting (r = .55) in patients with PD. Additional moderate to strong positive associations
(r = .49-.56) between DaT concentrations and visuospatial functions in patients with PD
were found. However, similar significant associations between DaT and cognition were
observed in age and education matched controls. Clinically, it is important for health
care professionals to consider the role of both striatal and extra-striatal mechanisms as
they relate to cognition in PD. Future studies examining the full range of pathological
mechanisms that contribute to cognitive dysfunction in PD over time are warranted in
order to inform more effective and targeted interventions.
KEYWORDS: Parkinson’s Disease, Dopamine, DaT, SPECT, Executive Functioning
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INTRODUCTION
1.1

Parkinson’s Disease
Parkinson’s disease (PD) is common neurodegenerative disorder that affects the

central nervous system. Approximately one million people are affected in the United
States alone, with about 66,000 new diagnoses made each year (Kowal, Dall, Charkabati,
Storm, & Jain, 2013). PD is characterized clinically by parkinsonism (e.g., tremor,
rigidity, akinesia, and postural instability) (Cummings et al., 2011; McPherson &
Cummings, 2009). One of the main neuropathological hallmarks of PD is dopaminergic
neuronal loss in the substantia nigra pars compacta (SNc) and accumulation of alphasynuclein protein aggregates (Lewy bodies) within neurons (Gunzler, Schoenberg, Riley,
Walter, & Maciuna, 2011; Jankovic, 2008).

Alpha-synuclein targets the autonomic

nervous system and the brainstem in PD, resulting in loss of dopaminergic neurons in the
SNc and other brainstem nuclei. Protein deposition then spreads to limbic structures
(e.g., the amygdala), the medial temporal lobe, and eventually the neocortex as the
disease progresses (Braak, Ghebremedhin, Rüb, Bratzke, & Tredici, 2004). Levodopa,
the precursor for dopamine (DA), has been successful in alleviating the motor symptoms
of PD, however, levodopa’s efficacy may decrease over time, with some patients
requiring alternative forms of treatment such as DA agonists or deep brain stimulation
(Gunzler, Schoenberg, Riley, Walter, & Maciuna, 2011).
1.2

Cognitive Impairment in PD
Much attention is often given to the motor symptoms of PD, however the wide

range of non-motor symptoms that accompany the disease can be just as debilitating and
are associated with reduced quality of life (Chaudhuri & Schapira, 2009). Cognitive
1

impairment occurs in 20-60% of patients with PD

(Getz & Levin, 2017; Gunzler,

Schoenberg, Riley, Walter, & Maciuna, 2011). The most frequently associated cognitive
impairment in PD is executive dysfunction, including problems with organization, setshifting, and inhibition (Kudlicka, Clare, & Hindle, 2011; Rodriquez-Oraz et al., 2009).
Executive dysfunction is one of the earliest cognitive impairments seen in PD and is
thought to be caused by reduced dopaminergic projections from the striatum to the frontal
cortex (Getz & Levin, 2017; Jankovic, 2008; Kudlicka, Clare, & Hindle, 2011). Other
cognitive impairments seen in PD include problems with attention, working memory,
speed of processing, language, and visuospatial abilities (Adams, 2009; Getz & Levin,
2017; Gunzler, Schoenberg, Riley, Walter, & Maciuna, 2011; Hirano, Shinotoh, &
Eidelberg, 2012).
In recent years, research has demonstrated a need to classify patients with PD who
have cognitive impairments, but do not have the functional impairments required for a
diagnosis of dementia. Approximately 25% of patients with PD have mild cognitive
impairment (MCI) (Weintraub & Mamikonyan, 2019). Various criteria for PD-MCI have
been proposed in the literature making it difficult to compare studies. Recently, the
movement disorders society (MDS) commissioned a task-force to define suggested
criteria to be used for PD-MCI (Litvan et al., 2012). PD-MCI is characterized by an
insidious decline in cognitive abilities caused primarily by the underlying disease
process. The cognitive decline may be reported by either the patient or an informant, or
observed by the clinician. These subjective cognitive concerns must be accompanied by
objective evidence of cognitive deficits on neuropsychological testing.

Finally, the

cognitive deficits in PD-MCI are not sufficient enough to interfere with functional
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independence (Litvan et al., 2012). The MDS criteria includes guidelines for level 1 and
level II diagnostic categories. The Level 1 category allows for PD-MCI to be diagnosed
based on an abbreviated cognitive assessment (e.g., a scale measuring global cognition
validated for use in PD or a limited battery of neuropsychological tests) as
comprehensive testing may not always be practical or available; however this method
provides less diagnostic certainty.

When using a limited neuropsychological battery,

Level I criteria requires impairment in at least two tests.

Level II criteria requires

comprehensive neuropsychological testing that includes at least two tests in the domains
of attention/working memory, executive, language, memory, and visuospatial functions.
Impairment must be present on at least two tests within a single domain or across
different cognitive domains. Impairment may be defined as 1-2 standard deviations (SD)
below normative data, a significant decline in serial testing, or a significant decline from
estimated premorbid levels. Level II criteria also allow for subtype classifications (i.e.,
single or multiple domain) and require specification of the affected domains (i.e.,
memory, visuospatial) (Litvan et al., 2012). MCI has prognostic value in predicting
conversion to dementia (Litvan et al., 2012; Williams-Gray et al., 2013), which occurs in
approximately 80% of patients with PD (Aarsland, Brown, Larsen, & Ballard, 2005;
Litvan et al., 2012; Weintraub & Mamikonyan, 2019).
1.3

Neuropsychiatric Disorders in PD
The most common psychiatric feature in PD is depression, with clinically

significant depressive symptoms occurring in approximately 30% of patients with PD
(Reijnders, Ehrt, Weber, Aarsland & Leentjens, 2008). Anxiety, apathy, and impulse
control disorders are common as well (Aarsland, Marsh, & Schrag, 2009).

3

The

pathophysiological bases of both cognitive and affective symptoms are complex and
likely involve dopaminergic, serotonergic, and noradrenergic systems (Aarsland, Marsh,
& Schrag, 2009; Halliday et al., 2014). Furthermore, these affective symptoms may
impair cognition and adversely affect neuropsychological performance (Adams, 2009;
Getz & Levin, 2017; Litvan et al., 2012). In addition, psychiatric symptoms can predate
the motor symptoms of the disease by several years (Aarsland, Marsh, & Schrag, 2009).
Finally, autonomic nervous system dysfunction is also prevalent in PD and can manifest
as difficulty swallowing, constipation, orthostatic hypotension, urinary leakage, or sexual
dysfunction (Gunzler, Schoenberg, Riley, Walter, & Maciuna, 2011; Jankovic, 2008).
1.4

The Basal Ganglia
The neuropathology of PD is associated with dysfunction of the basal ganglia.

The basal ganglia include the globus pallidi, caudate nuclei, putamina, substantia nigras,
and the subthalamic nuclei (see Figure 1.1). The nuclei of the basal ganglia are known to
initiate and control motor movement and are specifically important for the fine-tuning of
motor movement. When these areas are damaged, motor dysfunction such as tremor,
rigidity, and dyskinesias can emerge (Alexander, DeLong, & Strick, 1986; Gunzler et al.,
2011; Halliday et al., 2014; Jankovic, 2008).
The basal ganglia are heavily connected to the frontal lobes and communication
between the cortex and the basal ganglia is facilitated by multiple (closed) parallel
cortico-striato-thalamo-cortical (CSTC) loops (see Figure 2). Each circuit originates in
specific regions of the cerebral cortex (e.g., motor, oculomotor, dorsolateral,
orbitofrontal, and anterior cingulate), traverse specific regions of the basal ganglia (e.g.,
striatum, pallidum, and substantia nigra) and thalamus, and project back to one of the
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cortical areas, thereby completing the closed loop (Alexander, DeLong, & Strick, 1986).
These loops are divided into two motor (i.e., motor and oculomotor) and three
cognitive/behavioral (i.e., dorsolateral, orbitofrontal, and anterior cingulate) domains
(Alexander, DeLong, & Strick, 1986; Obeso et al., 2014). Although each CSTC circuit
constitutes a closed loop, open loop elements are incorporated into the connectivity as
well, including afferent and efferent projections to and from other cortical areas (e.g.,
temporal and parietal lobes) and thalamic and amygdalar nuclei (Bonelli & Cummings,
2007).

5

Figure 1.1 Cortico-striato-thalamo-cortical loops.
Diagram of the motor, associative (cognitive) and limbic cortico-striatal circuits. The
loops connect the cortex to the basal ganglia. Put = putamen; GPe = globus pallidus
externa; GPi = globus pallidus interna; STN = subthalamic nucleus; Cn = Caudate
nucleus. (Lapidus, Stern, Berlin, & Goodman, 2014).
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Each CSTC loop can be further divided into two pathways: the direct pathway
which increases movement and the indirect pathway which inhibits movement. In the
direct pathway, the motor cortex and substantia nigra pars compacta (SNc) excite the
striatum via the D1 dopamine receptor. When the striatum is excited, it sends inhibitory
signals (GABA) to the globus pallidus interna (GPi) and the substantia nigra pars
reticulata (SNr). Once the GPi and SNr are inhibited, the thalamus is free to send
excitatory signals (glutamate) to the motor cortex, thereby increasing movement. In the
indirect pathway, the motor cortex excites the striatum while the SNc inhibits the striatum
via the D2 dopamine receptor. This in turn inhibits the globus pallidus externa (GPe).
Once the GPe is inhibited, there is less inhibition of the subthalamic nucleus (STN),
which leads to excitation of the GPi. The GPi then sends inhibitory signals to the
thalamus, leading to less excitation of the motor cortex and therefore less movement.
The direct and indirect pathways create balance between competing excitatory and
inhibitory impulses; imbalance between these pathways results in dysfunction (Gunzler,
Schoenberg, Riley, Walter, & Maciuna, 2011). Recent research has demonstrated that
several cortical areas (e.g., the motor area, premotor cortex, anterior cingulate cortex,
dorsolateral prefrontal cortex, etc.) have excitatory projections directly to the STN,
creating an additional route beyond the direct and indirect pathways. These pathways are
collectively known as the hyperdirect pathway and serve as the quickest route for access
to output pathways (Jahanshahi, Obeso, Rothwell, & Obeso, 2015)
1.5

Dopamine Depletion and Dysfunction of Frontostriatal Loops
Although the basal ganglia loops were originally studied within the motor system,

we now know the important role that the basal ganglia play in regulating cognition. The

7

primary CSTC pathway of interest for this study is the pathway that connects the
prefrontal cortex and the striatum. The dorsolateral prefrontal cortex (DLPFC) loop
originates in the prefrontal cortex (Brodmann’s areas 9,10, and 46) and projects to the
dorsolateral head of the caudate nucleus (see Figure 1.2). The caudate then in turn
projects the GPi/SNr via the direct pathway. The indirect pathway sends fibers to the
GPe which projects to the STN and then terminates in the GPi/SNr. Output from the
basal ganglia is then projected to the thalamus, which in turn projects back to the
dorsolateral prefrontal cortex. Disruptions in the dopaminergic projections along this
pathway (i.e., loss of dopaminergic neurons in the SNc which projects to the striatum)
can lead to problems with EF (e.g., organization, mental flexibility, and problem solving)
(Getz & Levin, 2017; Jankovic, 2008; Poletti & Bonucelli, 2013).
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Figure 1.2. Coronal view of the brain showing the main basal ganglia nuclei and related
structures.
Striatum = caudate nucleus and putamen; GPe = globus pallidus externa; GPi = globus
pallidus interna; STN = subthalamic nucleus; SNc = substantia nigra pars compacta; SNr
= substantia nigra reticulate (Obeso, Rodriguez-Oraz, Stamelou, Bhatia, & Burn, 2014)
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Because of the spatiotemporal progression of the dopamine depletion, affecting
the dorsal striatum first, tasks associated with this region (e.g. set shifting and planning)
may improve with dopamine replacement therapy. In contrast, functions such as reversal
and implicit learning which are associated with the ventral striatum (i.e., ventral caudate,
putamen, and nucleus accumbens) may worsen due to “overdosing” these less dopamine
depleted brain regions (Cools, 2006; Getz & Levin, 2017; Poletti & Bonucelli, 2013).
Thus, the relationship between dopamine and performance follows an inverted U-shaped
function, such that both too little and too much dopamine can impair performance
depending on the type of task and the brain region recruited. Furthermore, different
individuals may have different baseline levels of dopamine and may demonstrate
differential sensitivity to the positive and negative effects of dopamine (Cools, 2006;
Cools & D’Esposito, 2011).

This individual variation may reflect an individual’s

position on the hypothetical inverted U-shaped curve (Cools, 2006).
Dopamine also plays a role in regulating affect. Dopaminergic disruptions in the
anterior cingulate pathway can lead to problems with motivation and apathy (Leisman,
Melillo, & Carrick, 2013). Apathy occurs in approximately 40% of patients with PD and
can occur independently of depression, although overlap is common (Weintraub &
Mamikonyan, 2019).

Dysfunction of the orbitofrontal circuit and lower striatal

dopamine transporter (DaT) levels can result in behavioral disinhibition in the form of
impulse control disorders (ICDs).

Impulse control disorders (ICDs) are common

neuropsychiatric disorders in PD with a prevalence of 14-43% (Smith, Xie, & Weintraub,
2014). ICDs can develop following the initiation of dopamine replacement therapy
(DRT), particularly with the use of D2- receptor selective dopamine agonists (Smith, Xie,
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& Weintraub, 2014; Vriend et al., 2014; Voon et al., 2014). The primary ICDs in PD are
compulsive gambling, eating, buying, and sexual behavior; these behaviors are performed
repetitively, excessively, and compulsively and can interfere with daily functioning
(Weintraub, David, Evans, Grant & Stacy, 2015). Therefore, the basal ganglia has
influence on a broad range of behavior, contributing to the heterogeneous nature of
symptom presentation in PD.
1.6

Dopamine Transporter Imaging
The diagnosis of PD formerly relied solely on the clinical exam; however,

establishing the cause of PD can be challenging, especially in the early stages of the
disease (Ravina et al., 2012). Pathological studies have documented that approximately
20-25% of clinically diagnosed cases of idiopathic PD are found to have alternative
diseases at autopsy, with most misdiagnosed cases having Progressive Supranuclear
Palsy (PSP), Multiple Systems Atrophy (MSA), Alzheimer’s Disease (AD), or vascular
parkinsonism (Adler et al., 2014; Hughes, Daniel, Kilford, & Lee, 1992). Early and
accurate diagnoses in patients with PD and other parkinsonism syndromes is important to
avoid unnecessary treatments associated with financial costs and side effects.
Dopaminergic dysfunction can be visualized using a molecular imaging technique
called the DaTscan, which measures the amount of DaT available in the striatum. DaTs
are presynaptic proteins located on the membrane of dopaminergic neuron terminals.
During excitation, their function is to transport dopamine out of the synaptic cleft and
back into the presynaptic nerve endings for either storage or degradation (Benamer et al.,
2002; Djang et al., 2012). The DaTscan uses a dopamine transporter radioligand (i.e.,
123-I-Ioflupane) along with single photon emission computed tomography (SPECT) to
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visualize the distribution of dopamine within the striatum. 123-I-Ioflupane (DaTscan) is
a cocaine analogue substance that is injected intravenously, with imaging enabled 3-6
hours after administration. 123-I-Ioflupane binds to the dopamine transporter and the
reduction of which correlates with loss of dopamine (Cummings et al., 2011).
The DaTscan was approved by the European Medicine Agency in 2000 and by
the Food and Drug Administration in the United States in 2011 for the clinical use of in
vivo diagnostic imaging of suspected parkinsonian syndromes (Bajaj, Hauser, &
Grachev, 2013).

The DaTscan can be used in patients with clinically uncertain

parkinsonism in order to help differentiate degenerative parkinsonian syndromes (e.g.,
PD, MSA, PSP, and Corticobasal Degeneration) from disorders that are not associated
with a striatal dopaminergic deficit (e.g., essential tremor and drug induced, vascular, or
psychogenic parkinsonism) (Bajaj, Hauser, & Grachev, 2013; Cummings et al., 2011;
Djang et al., 2012).
The DaTscan has demonstrated excellent sensitivity and specificity (Bajaj,
Birchall, & Jones, 2012; Suwijn et al., 2015). A study of 743 DaTscan cases performed
at the United Kingdom National Centre of Excellence for PD over a 9-year period found
a sensitivity of 99.4% and specificity of 98.6% when compared to clinical diagnosis
(Bajaj, Birchall, & Jones, 2012). A recent systematic review of eight DaT SPECT studies
using several different radiotracers found that the sensitivity and specificity of DaT
SPECT to detect nigrostriatal cell loss was 98% (Suwijn et al., 2015).

Certain

medications (e.g., anticholinergics, bupropion, radafaxine, and mazindol) and drugs of
abuse (e.g., amphetamines, and modafinil) are contraindicated with the scan as they bind
to the DaT with high affinity, potentially interfering with the DaTscan. Antiparkinsonian
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drugs including levodopa, dopamine agonists, monoamine oxidase-B inhibitors, and
catchol-O-methyl transferase inhibitors do not interfere with the DaTscan and do not
need to be withdrawn prior to scanning (Booij & Kemp, 2008).

1.6.1

Visual Interpretation and Quantitative Analysis

DaTscan results can be classified as normal or abnormal through visual
interpretation of the striatum, specifically by looking at the shape and symmetry of the
striata and degree of reduction (Park, 2012). A normal DaTscan (such as those typically
seen in patients with essential tremor) looks like two symmetric crescent-shaped areas of
radioligand uptake in the striatum in both hemispheres. An abnormal DaTscan shows
asymmetric or bilateral symmetric decrease in the size or color intensity of the
radioligand in the striatum (Park, 2012; Waln et al., 2015) (see Figure 1.3). The side with
relatively lower uptake generally matches contralaterally to the clinically more affected
side (Djang et al., 2012; Park, 2012). Several studies have yielded excellent results with
visual interpretation only (Benamer et al 2000; Catafau & Tolosa 2004; Tissingh et al.,
1998, Marshall et al 2009).

Imaging results can also be analyzed using

semiquantification methods, during which binding ratios are calculated by comparing
activity in the striatum with activity in an area of low DaT concentration, usually the
occipital lobe (Park 2012; Djang et al 2012). Semiquantification can be done manually or
by using automated software (Djang et al., 2012)

13

Figure 1.3. Normal and abnormal DaTscans. (Cummings et al., 2011)
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1.7

Review of Prior Dopamine Neuroimaging Studies
Dopamine transporter availability in the brain can be investigated using different

radioligands (e.g., 123-I-FP-CIT, 18F-FP-CIT, 99mTc-TRODAT, etc.) with SPECT or
positron emission tomography (PET) imaging. SPECT scans are much more available
and widely used compared to PET scans, however SPECT scans have lower image
resolution (Cummings et al., 2011; Djang et al., 2012). Studies investigating the
relationship between DaT availability and cognition have most prominently been
characterized by significant associations between dopamine and EF (Chung et al., 2018;
Cropley, Fujita, Innis & Nathan, 2008; Duchesne, Soucy, Masson, Chouinard & Bedard,
2002; Muller, Wachter, Barthel, Reuter, & von Cramon, 2000; Nobili et al., 2009;
Pellechia et al., 2015; Pollito et al., 2012; Rinne et al., 2000; Siepel et al., 2014). A study
by Duchesne and colleagues found reduced DaT binding in the left striatum was
associated with deficits in a simultaneous processing task in 10 patients with PD;
however, this relationship disappeared when patients were tested on their dopaminergic
medication

(Duchesne, Soucy, Masson, Chouinard & Bedard, 2002).

A similar

observation was found in a study of 20 PD patients in which DaT availability in both the
caudate and putamen were significantly associated with set-shifting, cognitive flexibility,
and working memory (Muller, Wachter, Barthel, Reuter, & von Cramon, 2000).
However, all of the associations disappeared after patients in the early stages of the
disease (i.e., Hoehn and Yahr stage < 2) were excluded, suggesting that disease severity
could have affected their results (Muller, Wachter, Barthel, Reuter, & von Cramon,
2000).

Another study investigated striatal dopamine in 26 patients with PD using

fluorodopa (i.e., FDOPA) PET scans.

FDOPA is another measure of presynaptic
15

dopamine commonly used with PET scans, however, it is also sensitive to noradrenergic
and serotonergic neurons, thus it does not solely reflect the activity of dopamine (Cropley
et al., 2008; Rinne et al., 2000). This study found that reduced FDOPA uptake in the
caudate correlated with impaired working memory, attention, and verbal fluency;
however, this study also consisted of six patients with dementia, which likely confounded
the results (Rinne et al., 2000).
Pollito and colleagues (2012) examined both DaT binding and brain glucose
metabolism using 18F-fluorodeoxyglucose (FDG) PET in 18 drug-naïve patients with
PD. The researchers found that impaired letter fluency was significantly associated with
reduced DaT in the caudate nucleus; furthermore, lower brain glucose metabolism in the
DLPFC, orbitofrontal cortex, and the anterior cingulate cortex was associated with worse
performance on letter fluency. Nobili and colleagues (2010) compared 30 de novo PD
patients and 15 patients with essential tremor (ET) and found that DaT availability in the
caudate was positively associated with EF.

Conversely, there were no significant

correlations between DaT and cognition in the ET control group (Nobili et al., 2010).
One study found an association between FDOPA in the putamen and the number of
categories achieved on the WCST (Cropley, Fujita, Innis & Nathan, 2008). In contrast
to the above studies, other studies have failed to find significant associations between
DaT availability in the striatum and EF (Jokinen et al., 2010; Kubler, Schroll, Buchert
&Kuhn, 2017).
A few studies have compared DaT imaging in PD patients with versus without
MCI. A study comparing 19 patients with PD and 15 with PD-MCI found lower caudate
and putamen DaT availability was associated with lower scores on the Frontal
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Assessment Battery (FAB), lower DaT in the caudate was related to lower scores on
Trailmaking B minus Trailmaking A (i.e., Trails B minus A), and lower DaT availability
in the caudate and putamen were associated with lower scores on the Rey-Osterrieth
Copy Figure test (ROCF) in patients with PD-MCI (Pellechia et al., 2015). There were
no significant correlations found between neuropsychological scores and DaT imaging in
PD patients without MCI (Pellechia et al., 2015). Chung et al. (2018) found DaT
availability in the caudate nucleus was positively associated with attention/working
memory, EF, and visuospatial function in a large sample of drug naïve PD patients with
and without MCI.

Additional associations were found between attention/working

memory, EF, language and visuospatial function and DaT binding in the ventral striatum.
Finally, a recent, large (N =339), multicenter study using patients from the Parkinson’s
Progression Markers Initiative (PPMI) found small but significant associations between
DaT availability and verbal memory and attention/executive functioning; however, after
adjusting for age none of the relationships were significant. Additionally, DaT binding
mediated the EF deficit in PD, and age moderated this effect such that the mediation
effect was stronger for younger patients than in older. The authors suggested that this
finding indicated that cognition in the older adults of their sample was likely influenced
by other neurotransmitters or structural changes (Siepel et al., 2014).
There is less data examining the extent that DaT availability contributes to
cognitive domains outside of EF. A study by Jokinen et al. (2010) found that caudate
FDOPA uptake correlated with verbal and visual memory performance in 19 patients
with PD.

This study also found that the PD patients had more atrophy in the

hippocampus and prefrontal cortex compared to controls through volumetric
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neuroimaging analysis, which may have partially explained their memory findings.
Muller and colleagues (2000) also found significant associations between DaT
availability in the striatum and verbal memory. A few studies have also found significant
associations between DaT availability in the striatum and performance on the ReyOsterrieth Copy Figure test (Chung et al, 2018, Pellechia et al., 2015), however the motor
component of this measure may have confounded these results.
In sum, the literature thus far has found significant relationships between the
striatal DaT availabilty and EF, although some studies have not (Jokinen et al., 2010;
Kubler, Schroll, Buchert & Kuhn, 2017).

Fewer studies have found relationships

between DaT availability and verbal (Jokinen et al., 2010; Muller et al., 2000) and visual
memory (Jokinen et al., 2010) as well as visuospatial functioning (Chung et al, 2018,
Pellechia et al., 2015). Some studies found cognition correlated with DaT availability
solely in the caudate (Pollito et al., 2012; Nobili et al., 2010, Pellechia et al., 2015; Rinne
et al., 2000), while DaT availability in both the caudate and putamen correlated with
cognition in other studies (Chung et al., 2018; Duchesne, Soucy, Masson, Chouinard &
Bedard, 2002; Muller et al., 2000; Siepel et al 2014).
1.7.1

Limitations of Prior Studies

There are several methodological issues that should be considered when
interpreting the results of prior studies. First, most of the previous studies included small
and heterogeneous samples, including patients at different stages of the disease and
patients both on and off dopaminergic medication. Furthermore, the neurocognitive
batteries utilized in the majority of these studies have been fairly limited and could
potentially underestimate the relationship between DaT and cognition, particularly in
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domains outside of EF. Although dopamine systems are mainly involved in prefrontal
executive functions, other cognitive domains have to be investigated from this
perspective. Additionally, various EF measures assess different aspects of the executive
functioning process, and thus may be differentially relatedly to dopaminergic activity.
Utilization of a broader neurocognitive battery, including additional EF tests, is
warranted to fully test these relationships.

Finally, differences in the spatial and

temporal resolution of PET vs. SPECT scanners, the use of different radioligands, and
variability in the striatal subregions analyzed likely also contribute to the inconsistencies
across studies.
1.8

Purpose of the Present Study
As described above, studies have looked at the relationship between DaT striatal

availability and cognition, however sample sizes have been small and heterogeneous
along with fairly limited neurocognitive batteries.

The present study utilized a

comprehensive neuropsychological battery assessing multiple domains (e.g., verbal and
visual memory, language, EF, processing speed, and visuospatial). Furthermore, given
the known role of dopaminergic dysfunction on EF abilities, more tests measuring EF
were included in the present study compared to prior studies.

The present study

retrospectively examined the relationship between striatal DaT availability using SPECT
and cognitive data within a consecutive series of PD patients. Using these data, we can
understand the relationship more specifically between measurable dopamine availability
in the brain and changes in reasoning, memory, decision-making, and affect. Some of
these relationships will teach us about the direct effects of Parkinson-induced changes in
brain structure and function that can be used for other critical areas, such as new
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treatment targeting. Based on the previous literature the following hypotheses were
tested:
1. Study Aim 1: Investigate the pattern of cognitive impairment in patients
with PD compared to age and education matched controls.
a. Hypothesis 1: Given, the role of striatal dopaminergic deficits in
cognition, we predicted that the PD group would demonstrate
worse scores on measures of attention, executive functioning,
learning, and memory when compared to age and education
matched controls.
i.

Power analysis: Based on a power analysis, a sample size
of 21 PD patients and 21 controls provided an achieved
power of 0.72 to detect a large effect (d = 0.8).

2. Study Aim 2: Examine the relationship between cognition and striatal DaT
availability in patients with PD at different striatal regions of interest (e.g.,
left and right striatum, left and right caudate nucleus, and left and right
putamen)
a. Hypothesis 2: We expected DaT availability in the striatum to
correlate with measures of executive functioning, learning, and
memory. Furthermore, we expected moderate to strong positive
correlations between executive functioning measures and DaT
availability in the caudate nucleus, specifically.
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i.

Power analysis: Based on a power analysis, the sample size
of 21 PD patients provided an achieved power of 0.71 to
detect a large effect (r = .50).

METHOD
2.1

Participants
The present study was a retrospective chart review. The data was obtained from a

movement disorders clinical database at the Norton Neuroscience Institute Nuclear
Medicine Department in Louisville, Kentucky. All subjects in the PD group received a
diagnosis of idiopathic PD by a movement disorders neurologist. The patients without
dopaminergic deficit on DaTscan were chosen for the comparison group in order to
highlight the differences in cognition directly resulting from differences in DaT
availability in the basal ganglia. Twelve of the control participants had a diagnosis of
ET, a non-neurodegenerative disorder typically associated with a normal DaTscan.
Exclusion criteria for both groups included dementia, history of major stroke(s),
structural lesions, chronic use of antipsychotics or neuroleptics, and major psychiatric
disorders. We did not exclude for depression or anxiety in the PD group because PD
patients commonly report such symptoms.
2.2

Procedure
2.2.1

DaTscan

All subjects received an intravenous injection of 3-5 millicurie (mCi) of 123-IIoflupane after oral administration of a thyroid-blocking agent (Lugols Solution) one
hour prior to the scan. Patients were instructed to stop taking drugs that may alter the
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tracer binding (e.g., amphetamines, methylphenidate, ephedrine, phentermine, bupropion,
fentanyl, and some anesthetics) for at least 5 half lives. SPECT imaging was conducted
3-6 hours post-injection of the radiotracer. Imaging lasted approximately 30-40 minutes.
A gamma camera fitted with high-resolution collimators and set to a photo peak of 159
keV with a + 10% energy window was utilized for SPECT imaging.

Images were

acquired using a 128 x 128 image matrix (pixel size between 3.5 and 4.5 millimeters) and
reconstructed using a Butterworth filter. Images were corrected for attenuation using
Chang’s algorithm.

Expert readers in the nuclear medicine department at Norton

Neuroscience Institute performed visual interpretation of the DaTscan. Scans were read
clinically as either showing evidence of DaT deficit (i.e.. abnormal) or not showing
evidence of dopamine transporter deficit (i.e., normal).
Basal ganglia regions of interest (ROIs) were generated using the MIM
Neuroimaging software. This software uses an anatomic atlas (i.e., MIM DaTscan atlas)
that was created by defining volumes of interest on 10 high resolution T1 weighted MRI
scans. Each of the MRI scans were then registered to a template space using their coregistered SPECT scans. Manual realignments were made when necessary to adjust the
generated ROI to the boundaries of the respective DaTscan. Anatomic interrater
reliability across two raters was excellent ICC = 0.98, 95% CI [0.96-0.99]. Mean DaT
counts for each striatal subregion in both hemispheres were generated by the MIM Neuro
software and used for analyses.
2.2.2

Neuropsychological Assessment

Raw test scores were standardized into z-scores based on demographically
published norms. To reduce the number of analyses, individual test z-scores were then
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averaged into z-score composites determined a priori. The composite groupings were
based on the cognitive domains discussed within the clinical neuropsychological
literature (Lezak, Howieson, Bigler, & Tranel, 2012). Due to the large number of EF
tests which tapped different aspects of EF, the EF composite was split into subdomains
rather than utilizing a unitary EF composite. Executive functions are separable and
different executive functions contribute differently to various complex executive tasks
(Lezak, Howieson, Bigler, & Tranel, 2012). EF measures were subject to a factor
analysis by principal components using an orthogonal (Varimax) rotation.

Factor

analysis confirmed a 5-factor structure accounting for 93.25% of the total variance in EF.
The first factor (problem solving/set-shifting) accounted for 25.84% of the variance. The
second factor (inhibition) accounted for 21.30% of the variance.

Verbal fluency

accounted for 17.18% of the variance. The final two factors, mental flexibility and
abstract reasoning, accounted for 15.85 and 13.08% of the variance, respectively.
The verbal memory domain consisted of the Hopkins Verbal Learning TestRevised (Trials 1-3 and delayed recall) and the immediate and delayed recall scores from
the Neuropsychological Assessment Battery (NAB) List Learning test. Visual memory
was assessed using the NAB Shape Learning test (immediate and delayed recall).
Language measures included the Boston Naming Test (BNT) and NAB Naming.
Visuospatial functioning was assessed using the Benton Judgment of Line Orientation
(JLO) test. Processing speed was measured using Oral Trails A. EF was divided into 5
subdomains: mental flexibility (Oral Trails B), inhibition (Delis-Kaplan Executive
Functioning System Color Word Interference Test (D-KEFS) Conditions 3 and 4), verbal
fluency (Controlled Oral Word Association Test (COWAT) and Animals), abstract
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reasoning (Wechsler Adult Intelligence Test- Fourth Edition (WAIS-IV) Similarities
subtest), and problem solving/set-shifting (Wisconsin Card Sorting Test (WCST) total
errors and perseverative errors). Affective measures included the Apathy Evaluation
Scale (AES) and the Barratt Impulsiveness Scale (BIS).
2.3

Measures
2.3.1

Descriptive Measures

2.3.1.1 Demographic and Clinical Measures
Demographic information was extracted from each patient’s medical record (e.g., age,
education, estimated premorbid IQ, gender, and ethnicity).

Additionally, clinical

measures of disease duration, levodopa equivalent daily dosage (LEDD), nondopaminergic medications, and modified Hoehn and Yahr (HY) stage were also collected
for each individual. The modified HY scale is a measure of disease severity in PD and
ranges from 1-5, with higher stages correlating with neuroimaging studies of
dopaminergic loss (Goetz et al., 2004).
2.3.2

Neuropsychological Measures

2.3.2.1 Hopkins Verbal Learning Test-Revised
The HVLT-R (HVLT-R; Brandt & Benedict, 2001) is a task of verbal learning and
memory. The task consists of a 12-item word list presented 3 times in the same order,
with a test of recall after each trial. The measure also includes a test of delayed recall and
recognition. The test has shown evidence of convergent validity with other measures of
verbal memory, such as the CVLT-II. The measure is sensitive to cognitive deficits
associated with a variety of neurological conditions (e.g., dementia, traumatic brain
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injury, mood disorders, and substance abuse). (Lezak, Howeison, Bigler, & Tranel,
2012; Strauss, Shermann & Spreen, 2006).
2.3.2.2 NAB List Learning
The NAB List Learning (Stern & White, 2003) subtest assesses verbal learning and
memory. The measure consists of a 12-item word list presented across three trials,
followed by an interference list, short and long delayed free recall, and forced-choice
recognition (Strauss, Shermann & Spreen, 2006). NAB List Learning recall scores have
demonstrated moderate validity levels with the CVLT-II recall (i.e., r = .43 for immediate
recall and r = .59 for short delay recall) (Lezak, Howeison, Bigler, & Tranel, 2012).

2.3.2.3 NAB Shape Learning
The NAB Shape Learning (Stern & White, 2003) subtest is a measure of visual learning
and memory. The task consists of three learning trials of nine target nonsense shapes.
Each learning trial is followed by a multiple choice recognition test in which each correct
target is paired with three foils. The subtest also consists of a delayed recall and forcedchoice recognition trial (Lezak, Howeison, Bigler, & Tranel, 2012; Strauss, Shermann &
Spreen, 2006). This task does not require a motor response, thus it is an ideal assessment
of visual memory in populations who may have compromised motor abilities.
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2.3.2.4 Boston Naming Test
The BNT (Kaplan, Goldglass & Weintraub, 1978) is a measure of visual confrontation
naming ability. The test consists of 60 line drawings of objects with increasing range of
difficulty. Semantic and phonemic cues are provided if necessary and are useful in
differentiating between problems with storage of information vs. problems with retrieval
(Lezak, Howeison, Bigler, & Tranel, 2012; Strauss, Shermann & Spreen, 2006). This
measure elicits naming impairments in a variety of neurological conditions. (Strauss,
Shermann & Spreen, 2006).
2.3.2.5 NAB Naming
The NAB (Stern & White, 2003) naming subtest requires the examinee to name pictured
items. Semantic and phonemic cues are provided if necessary. (Strauss, Shermann &
Spreen, 2006). Forms 1 and 2 of NAB Naming are moderately correlated (r = .45 and r =
.50, respectively) with the BNT (Yochim, Kane, & Mueller, 2009).

2.3.2.6 Benton Judgment of Line Orientation
The JLO (Benton, Hannay, & Varney, 1975) measures the ability to estimate angular
relationships between line segments and is a measure of spatial perception and orientation
(Lezak, Howeison, Bigler, & Tranel, 2012; Strauss, Shermann & Spreen, 2006). This test
consists of 30 pairs of angled lines to be matched to display cards. JLO impairment has
been reported in a variety of conditions known to affect visuospatial ability including
left-visual neglect, Parkinson’s Disease, and dementia. This measure has high internal
consistency (.90) and demonstrated validity. In addition, this measure does not require
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motor skills and demands little to no verbal mediation. (Strauss, Shermann & Spreen,
2006).
2.3.2.7 Oral Trailmaking A and B
Oral TMT (Ricker & Axelrod, 1994) is an alternative version of the Trailmaking Test A
& B and is often used with populations with motor deficits or visual impairment. The
test is divided into two parts, A and B. In part A, the examinee is asked to count from 1
to 25 as quickly as possible. Part B asks the examinee to alternate between numbers and
letters aloud up to 13. Scores are obtained for time and errors. The correlations between
the oral and written versions are moderately strong (r= -.68 for part A; r =-.72 for part B)
(Ricker & Axelrod, 1994).

2.3.2.8 D-KEFS System Color-Word Interference Test
The D-KEFS (Delis, Kaplan, & Kramer, 2001) Color-Word Interference Test is a variant
of the Stroop procedure and measures inhibition of a prepotent response and mental
flexibility (Strauss, Shermann & Spreen, 2006). The present study utilized Conditions 3
and 4. Condition 3 requires the examinee to name the color of the ink in which the words
are printed. Condition 4 requires the examinee to switch back and forth between naming
the dissonant ink colors and reading conflicting words (Strauss, Shermann & Spreen,
2006). Internal consistency for Conditions 3 and 4 are adequate. Several studies have
documented that performance on the D-KEFS is affected by frontal lobe lesions and
subcortical disease (Lezak, Howeison, Bigler, & Tranel, 2012).
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2.3.2.9 Controlled Oral Word Association Test
The COWAT (Reitan & Wolfson, 1985) is a test of phonemic fluency and is part of the
Expanded Halstead-Reitan Neuropsychological Battery.

The COWAT requires the

examinee to say as many words as the individual can think of that begin with a specified
letter in one minute. The present study used the standard version with the letters F, A,
and S. Reduced capacity to generate words on the COWAT is a sensitive indicator or
brain dysfunction (Lezak, Howeison, Bigler, & Tranel, 2012). FAS has demonstrated
high test-retest reliability and correlates highly with other letter sets (e.g., CFL and PRW)
(Strauss, Shermann & Spreen, 2006).

2.3.2.10 Animals
The “Animals” (Reitan & Wolfson, 1985) category is the most common category used to
test semantic fluency. The test requires the examinee to orally produce as many animals
as possible within one minute. “Animals” is sensitive to impaired verbal fluency in PD
(Henry & Crawford, 2004). There is evidence that semantic fluency tests are more useful
than other neuropsychological tests in the detection of dementia and discrepancies
between phonemic and category fluency may be useful in distinguishing cortical and
subcortical dementias ( Lezak, Howeison, Bigler, & Tranel, 2012).

2.3.2.11 Wechsler Adult Intelligence Scale-Fourth Edition Similarities Subtest
(WAIS-IV Similarities) Similarities is a test of verbal concept formation and requires the
examinee to state how two concepts are alike. Relatively depressed Similarities scores
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tend to be associated with left temporal and frontal involvement. (Lezak, Howeison,
Bigler, & Tranel, 2012).

2.3.2.12 Wisconsin Card Sorting Test
The WCST (Berg, 1948; Grant & Berg, 1948) measures the ability to form abstract
concepts, to shift and maintain set, and to utilize feedback. The WCST is one of the most
commonly used measures to assess executive functions and provides information
regarding problem-solving behavior. The test consists of two decks of 64 response cards,
which have designs similar to four stimulus cards. The participant is asked to match each
of the response cards to one of the four stimulus cards and is given feedback on whether
he or she is right or wrong each time. Several component scores provide information
regarding the examinee’s strategy and problem-solving behavior while completing the
test (e.g., the number of categories achieved, total errors, perseverative errors, and
perseverative responses). Perseverative errors occur either when the examinee continues
to sort to a previously successful principle or when the participant continues to sort on the
basis of an initial error. The perseverative error score may be useful in documenting
problems in forming concepts, benefitting from correction, and conceptual flexibility. A
correct response may also be counted as a perseverative response if it matches a
previously correct category (Strauss, Shermann & Spreen, 2006).

2.3.2.13 Barratt Impulsiveness Scale
The BIS (Barratt, 1959) is a 30-item self report measure of impulsivity. The responses
load on three 2nd order factors (i.e., Attentional, Motor, and Nonplanning Impulsiveness).
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Attentional impulsiveness is defined as an inability to focus attention or concentrate,
motor impulsiveness involves acting without thinking, and non-planning impulsiveness
refers to a lack of forethought (Stanford et al., 2009).

2.3.2.14 Apathy Evaluation Scale
The AES (Marin, Biedrzycki,& Firinciogullari, 1991) is a measure of apathy and assesses
the behavioral, cognitive, and emotional components associated with goal-directed
behavior. A score greater than or equal to 14 indicates the presence of apathy. There are
three versions (e.g., self, informant, and clinical). The present study used the self-report
version of the AES (Marin, Biedrzycki,& Firinciogullari, 1991).

2.4

Data Analysis
Alpha was set at p < .05 for all inferential tests. Chi-square tests were used to

determine demographic equivalence between the groups. The Mann-Whitney U test was
used in the case of non-normally distributed variables. Independent samples t-tests were
used to examine mean-level differences in striatal DaT availability between the PD and
control group. The association between neurocognitive measures and DaT availability
for each ROI was calculated using the Pearson’s product-moment correlation coefficient
matrix. Pearson’s correlations were also used to test the association between mean DaT
availability and affect. Partial correlations were utilized when appropriate.
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3
3.1

RESULTS

Outliers and Normality
Descriptive statistics revealed that most continuous variables were normally

distributed. Examination of skewness and kurtosis statistics, scatterplots, and boxplots
revealed no problematic outliers or significant skewness or kurtosis for most variables.
However, there were two neurocognitive variables that exhibited some skewness and
kurtosis (Oral Trails A and Oral Trails B). To correct for this, three outliers for the Oral
Trails A variable and two outliers for the Oral Trails B variable were identified using the
criteria of > 3 SD from the mean and were not included in the analyses. Additionally, the
distribution of HY stages was negatively skewed (Skewness statistic = -1.216, SE =
.501), thus non-parametric analyses were utilized for this variable.
3.2

Demographic Characteristics
As previously noted, participants were identified from archival clinical database

at Norton Neuroscience Institute. There were 73 available cases with both a DaTscan
and neuropsychological testing data, including 34 patients with an abnormal DaTscan and
43 controls with a normal DaTscan. Of the 34 participants with an abnormal DaTscan,
patients were excluded for the following reasons: dementia (n = 11), incomplete
neuropsychological test data (n =1) and poor effort on neuropsychological testing (n =1).
Of the 43 participants with a normal DaTscan and neuropsychological test data, 22
participants were excluded for the following reasons: dementia (n = 8), neurologic
disorder (n = 4), major psychiatric disorder (n = 6), structural lesion (n =1), chronic
antipsychotic use (n =2), and incomplete neuropsychological test data (n =1). This
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resulted in a final sample size of 42 participants, including 21 participants with PD and
21 age and education matched controls.
Demographic characteristics and clinical information of the sample are presented
in Table 3.1. PD and control participants did not differ significantly on age, education,
race, and gender variables. The overall sample was 90.5% Caucasian and 57.1% percent
male. Additionally, 90.5% of the sample was right handed. The PD group had a mean
age of onset of 61.45 years (SD = 11.83) and mean disease duration of 4.80 years (SD =
5.08). HY stage of the PD group ranged from 1-2.5, with a mean of 1.95 (SD =0.44).
Three PD patients were at HY stage 1 of the disease, 14 were at stage 2, and four at stage
2.5. Fifteen of the 21 PD patients were taking dopaminergic medication at the time of
the DaTscan and 19 at the time of the neuropsychological evaluation. The mean LEDD at
the time of the DaTscan (M = 978.71; SD = 646.606) was statistically significantly higher
than the mean LEDD during the neuropsychological evaluation (M= 432.38; SD =
408.374) (t = 6.94. p = .000).
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Table 3.1. Descriptive Statistics by Group
PD

C

n = 21

n = 21

t or Χ2

p

Age DaTscan

M (SD)

66.67 (11.16)

68.43 (8.85)

-0.57

0.58

Age NP

M (SD)

67.14 (10.49)

68.29 (8.67)

-0.39

0.70

Education

M (SD)

13.71 (2.37)

14.48 (3.09)

-0.90

0.38

Gender

% Male

62.0%

52.0%

0.39

0.53

% Caucasian

91%

91%

1.33

0.51

Race
Age Sx Onset

M (SD)

61.45 (11.83)

Disease Duration

M (SD)

4.80 (5.08)

Hoehn and Yahr

M (SD)

1.95 (0.44)

LEDD DaTscan

M (SD) 432.38 (408.374)

LEDD NP

M (SD)

978.71 (646.06)

Note: PD, Parkinson’s Disease patient group; C, Controls; M, Mean; SD , Standard
Deviation; NP, Neuropsychology; Sx, Symptom; LEDD, Levodopa Equivalency Daily
Dosage
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3.3

Group Differences in DaT Imaging
Table 3.2 presents mean group differences for DaT availability in each striatal

ROI by group.

The left striatum value is a composite of the left caudate nucleus

putamen, and the right striatum is a composite of the right caudate nucleus and putamen.
Significant group differences at p < 0.01 level were found in each of the striatal ROIs
analyzed: left striatum (t= -3.45, p = 0.001), left caudate (t= -2.96, p = 0.005), left
putamen (t = -3.75, p = 0.001), right striatum (t = -3.33, p = 0.001), right caudate (t = 2.64, p = 0.012), and right putamen (t = -3.69, p = 0.001). In all instances the PD group
had significantly lower mean counts of DaT availability in each striatal ROI.
Additionally, Table 3.2 shows that group differences in mean counts of DaT at each ROI
demonstrated large effect sizes (d= 0.81-1.14). A graphical depiction of the mean group
differences on DaT availability are presented in Figure 3.1. Paired sample t tests were
used to examine laterality differences in mean DaT availability within each group. There
were no significant differences between DaT availability in the left and right striatum (t
=-1.96, p = .06), left and right caudate (t =-1.55, p = 0.14), or left and right putamen (t =2.21, p = 0.04) in the PD group. In the control group the left putamen had significantly
lower mean DaT availability than right putamen (t =-3.26, p = 0.004), despite being
clinically read as normal. There were no significant differences between left and right
striatum (t = -1.74, p = 0.10) and left and right caudate (t = -.013, p =0.99).
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Table 3.2. Group differences in DaT availability
PD
n = 21

C
n = 21

p

d

Left striatum

M (SD)

23.65 (9.62)

36.41 (13.99)

0.001

1.06**

Left caudate

M (SD)

26.01 (10.55)

38 (15.37)

0.005

0.91**

Left putamen

M (SD)

21.89 (9.50)

35.15 (13.19)

0.001

1.15**

Right striatum

M (SD)

24.54 (10.32)

37.33(14.28)

0.001

1.03**

Right caudate

M (SD)

26.89 (11.26)

38.08 (15.83)

0.012

0.81**

Right putamen

M (SD)

23.41 (9.96)

37.01 (13.68)

0.001

1.14**

fdfd

Note: PD, Parkinson’s Disease; C, Control; M, Mean; SD, Standard Deviation
** p < .01
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Figure 3.1. Bar graph depicting group differences on DaT availability
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Control

3.4

Group Differences on Cognitive Composites
Hypothesis 1 aimed to examine group differences on neurocognitive measures

between the PD group and controls.

There were no statistically significant group

differences on any of the cognitive composites (Table 3.3).

Both PD and control

participants mean z-scores were within the normal range, not exceeding 1.5 SD. The
mean scores of only two domains across both groups (i.e., verbal memory and processing
speed) were greater than 1 SD; however as stated previously, group performances were
statistically comparable on these domains. Therefore, Hypothesis 1 was not supported in
that the PD group did not perform statistically worse on measures of executive
functioning, learning, and memory compared to controls.
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Table 3.3 Group differences on cognitive composites
PD
n = 21

C
n = 21

p

M

0.39

0.13

(SD)

(0.70)

(1.01)

M

-1.25

-1.02

(SD)

(1.15)

(1.04)

M

-0.12

-0.32

(SD)

(1.01)

(1.13)

M

0.01

-0.01

(SD)

(1.13)

(1.11)

M

-1.10

-1.37

(SD)

(0.67)

(1.00)

M

0.10

(SD)
M

d

0.34

0.31

0.51

0.21

0.47

0.22

0.96

0.02

0.41

0.36

-0.54

0.66

0.16

(0.77)
-0.42

(1.04)
-0.87

0.35

0.34

(SD)

(1.30)

(1.36)

M

-0.69

-0.76

0.86

0.06

(SD)

(1.18)

(0.98)

M

-0.54

-0.51

0.99

0.004

(SD)

(0.74)

(0.64)

M

-0.52

-0.68

0.67

0.17

(SD)

(0.95)

(0.88)

Language
(z-score)
Verbal Memory
(z-score)
Visual Memory
(z-score)
Visuospatial
(z-score)
Processing Speed
(z-score)
Mental Flexibility
(z-score)
Inhibition
(z-score)
Verbal Fluency
(z-score)
Abstract Reasoning
(z-score)
Problem Solving/Set-Shifting
(z-score)

Note: M, Mean; SD, Standard Deviation; PD, Parkinson’s Disease; C, Controls; EF, Executive Functioning
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3.5

DaT and Cognitive Composites: PD Group
Hypothesis 2 predicted that DaT availability in the striatum would be significantly

related to performance on measures of executive functioning, learning, and memory. It
was further predicted that the association between DaT and executive functioning would
be strongest in the caudate nucleus. Table 3.4 provides Pearson’s correlations between
mean DaT availability and cognitive composites for the PD group only. Regarding
executive functioning, there was a strong positive relationship (r =. 55, p = .03), between
DaT availability in the left caudate and the problem solving/set-shifting composite, such
that increased DaT availability was associated with better problem solving/set-shifting
abilities (see Figure 3.2). Strong relationships (r = .52-.61) were found between DaT
availability and verbal memory in all striatal ROIs (e.g. left striatum, left caudate, left
putamen, right striatum, right caudate, and right putamen), such that increased DaT
availability was associated with stronger verbal memory performance for PD patients.
The strongest association was between DaT availability in the right caudate and verbal
memory and is presented in Figure 3.3. Finally, there were modest to strong positive
correlations (r = .49-.56) between DaT availability in all ROIs and visuospatial
functioning, such that higher DaT availability was significantly related to better
performance on the JLO.
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Table 3.4 Pearson’s correlations between DaT availability and cognitive composites in
PD
LS

Verbal Memory
EF Composite 1

LC

LP

RS

RC

RP

.548*

.543*

.518*

.594**

.611**

.578**

Visual Memory

.234

.283

.176

.248

.250

.243

Language

.167

.091

.221

.122

.145

.108

Visuospatial

.551*

.511*

.541*

.521*

.562*

.492*

Processing Speed

-.135

-.019

-.222

-.160

-.059

-.214

Mental Flexibility

-.157

-.057

-.226

-.173

-.127

-.196

Inhibition

.336

.358

.289

.344

.404

.306

Verbal Fluency

.011

.156

-.113

-.036

.067

-.091

Abstract Reasoning

.248

.260

.220

.186

.209

.170

Problem Solving/Set Shifting .490

.549*

.390

.512

.510

.506

Note: LS=Left Striatum; LC= Left Caudate; LP= Left Putamen; RS=Right Striatum; RC=
Right Caudate; RP= Right Putamen
* p < .05, ** p < .01
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Figure 3.2. Scatterplot showing the correlation between problem solving/set-shifting and
DaT availability in the left caudate region of interest
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Figure 3.3 Scatterplot showing the correlation between verbal memory and DaT
availability in the right caudate region of interest
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Correlations between potential confounding variables (e.g. depression, LEDD,
disease duration, and HY stage) were examined to determine whether there was a need to
control for these variables. HY stage was significantly positively associated with DaT
availability in all ROIs ( rs= .45-.55) . Given the significant relationships between HY
stage and DaT availability, partial correlations were utilized to examine the relationship
of DaT and cognition while controlling for Hoehn and Yahr stage. Table 3.5 provides the
partial

correlations

for

relationships

between

DaT

availability

and

verbal

learning/memory, problem solving/set shifting, and visuospatial domains when
controlling for HY stage within the PD group only. Partial correlations between DaT
availability and verbal memory and DaT availability and visuospatial skills were
generally in the medium to large range (Table 3.5). The correlation between DaT
availability and problem solving/set shifting was no longer significant after controlling
for HY stage. There was no need to statistically control for other suspected confounding
variables (e.g. depression, LEDD, and disease duration) due to the lack of significant
relationships.
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Table 3.5 Partial correlations between DaT availability and cognitive composites
in PD controlling for Hoehn and Yahr stage
LS

Verbal
Memory
EF
Visuospati
Composite
al
Problem
1
Solving/Set
Shifting

.479*
.518*
.470

LC

.373
.512*
.467

LP

RS

.461*
.471*
.521

.528*
.529*
.493

RC

.534*
.565*
.527

RP

.454*
.422
.493

Note: LS=Left Striatum; LC= Left Caudate; LP= Left Putamen; RS=Right Striatum;
RC= Right Caudate; RP= Right Putamen
* p < .05, ** p < .01

44

Hypothesis 2 was partially supported such that increased DaT availability was
significantly associated with better performance on measures of verbal memory and
problem solving/set shifting as predicted.

The positive association between DaT

availability and problem solving/set shifting was significant within the caudate nucleus
specifically, consistent with our hypothesis. Additionally, the significant associations
between DaT availability and both verbal memory and visuospatial functioning were
strongest in the caudate nucleus.

Contrary to our hypothesis, there were not any

significant relationships between DaT availability and visual memory or other aspects of
EF (e.g., mental flexibility, inhibition/switching, verbal fluency, and abstract reasoning)
within the PD group.
3.6

DaT and Cognitive Composites: Control Group
Similar to the PD group, large positive relationships (r = .54-.59) were found

between the verbal memory composite and several ROIs (e.g. left striatum, left caudate,
left putamen, and right striatum) (Table 3.6).

Additionally, DaT availability in the

control group was significantly related to some aspects of EF.

Strong positive

relationships (r= .68-.72) were found between DaT availability in all striatal ROIs and the
inhibition composite, such that higher levels of DaT availability were associated with
better ability to inhibit a prepotent response. Increased DaT in the left caudate and right
putamen were significantly associated with better problem solving/set shifting (r = .61
and .60, respectively). In sum, in age and education matched controls there were strong
positive correlations found between DaT availability and verbal memory and subdomains
of EF.
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Table 3.6 Pearson’s correlations between DaT availability and cognitive composites in
Controls
LS
Verbal
Memory
EF Composite
Visual
1
Memory
Language
Visuospatial
Processing
Speed
Mental
Flexibility
Inhibition
Verbal
Fluency
Abstract
Reasoning
Problem
Solving/Set
Shifting

LC

LP

RS

RC

RP

.573*
*
.185
.366

.543*

.589**

.585**

.580

-.329

.232
.414

.133
.295

.131
.386

.194
.448

.096
.346

.256
.401
.396
.702
**
.325
.285

.250
.407
.371
.681*

.258
.391
.412
.711**

.272
.426
.390
.708**

.295
.425
.415
.715**

.314
.249

.332
.313

.324
.279

.226
.422
.340
.687
**
.343
.218

.590

.606*

.568

.602

.593

.604*

.318
.312

Note: LS=Left Striatum; LC= Left Caudate; LP= Left Putamen; RS=Right
Striatum; RC= Right Caudate; RP= Right Putamen
* p < .05, ** p < .01
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3.7

Exploratory analyses: Correlations between DaT and Affect
Additional exploratory analyses were conducted to examine the relationship

between DaT availability and symptoms of apathy and impulsivity. Table 3.7 presents
group differences on the AES and BIS. There were no statistically significant group
differences on self-reported symptoms of apathy and impulsivity between the PD group
and controls. Table 3.8 presents Pearson’s correlations between DaT availability and
affective measures. In the PD group, there was a strong negative correlation (r =-.62, p =
.01) between DaT in the left putamen and motor impulsiveness on the BIS, such that
decreased DaT was associated with greater motor impulsiveness (see Figure 3.4).
Further, a strong negative correlation was found between mean DaT availability in the
left striatum (r = -.56, p = .03) and motor impulsiveness (see Figure 3.5). Given the
significant relationships between and HY stage and DaT, partial correlations were
utilized to examine the relationship between DaT and motor impulsiveness while
controlling for HY stage. When controlling for HY stage, partial correlations remained
significant for relationships between DaT and both the left putamen (r = -.56, p = .04)
and left striatum (r = -.54, p = .04). There were no significant associations between DaT
availability and symptoms of affect within the PD group. Finally, neither apathy nor
impulsivity was significantly associated with DaT availability in the control group.
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Table 3.7 Group differences on affective measures
PD
n=
14
AES

BIS Total
(z-score)
BIS Att Imp
(z-score)
BIS Motor
Imp (z-score)
BIS Nonp
Imp (z-score)

C
n=
11

p

M

11.27

15.00

(SD)

(6.92)

(7.79)

M

-0.31

-0.01

(SD)

(1.27)

(0.97)

M

-0.36

-0.81

(SD)

(1.17)

(0.90)

M

-0.24

-0.69

(SD)

(1.11)

(0.81)

M

-0.12

0.45

d

0.21

0.51

0.51

0.27

0.52

0.43

0.26

0.46

0.23

0.28

(SD)
(1.18)
(1.18)
Note: M, Mean; SD, Standard Deviation; PD, Parkinson’s Disease; C,
Controls; AES, Apathy Evaluation Scale; BIS Total, Barratt Impulsiveness
Total Score; BIS Att Imp
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Table 3.8 Pearson’s correlations between DaT uptake and affective measures in PD
LS

RS
LC

RC

RP

LP

.019
-.099
-.052
-.075
-.037
.03
AES
6
BIS Total
-.309
-.424
-.305
-.339
-.282
.367
BIS Att Imp
-.159
-.221
-.151
-.216
-.113
.191
BIS Motor
-.483
-.622*
-.480
-.483
-.473
Imp
.555
BIS Non
-.209
-.319
-.218
-.232
-.208
*Planning Imp
.26
3 LC= Left Caudate; LP= Left Putamen; RS=Right Striatum;
Note: LS=Left Striatum;
RC= Right Caudate; RP= Right Putamen; AES, Apathy Evaluation Scale; BIS
Total, Barratt Impulsiveness Total Score; BIS Att Imp
* p < .05, ** p < .01
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Figure 3.4 Scatterplot showing the correlation between motor impulsiveness and
DaTscan availability in the left putamen region of interest
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Figure 3.5. Scatterplot showing the correlation between motor impulsiveness and
DaTscan availability in the left striatum region of interest
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DISCUSSION
4.1

Overview of the Findings
Although PD is defined classically by motor symptoms, non-motor deficits (e.g.,

cognitive, affective, and autonomic abnormalities) form an important part of the disease.
Greater understanding about the neuropathology underlying the cognitive and emotional
sequelae of PD is of the utmost importance in order to potentially enhance treatment
planning.

The current study aimed to elucidate the relationship between striatal

dopamine and cognitive functioning in patients with PD using neuroimaging,
neuropsychological, and psychological methods.

Additional exploratory analyses

examined the relationship between dopamine and affect (i.e., apathy and impulsivity).
An innovative aspect of this project was the exploration of these relationships using a
comprehensive neuropsychological battery that covered multiple cognitive domains, as
well as assessing the regional effects of DaT availability on cognition in PD.
4.2

Cognition in PD versus Controls
Although the PD group did demonstrate significant reductions of DaT in all

striatal ROIs compared to controls, this did not translate into reduced neurocognitive
deficits in the PD group as predicted. Contrary to our hypothesis, the PD group did not
demonstrate statistically worse performance on cognitive tasks that are associated with
frontostriatal dysfunction (e.g., attention, learning, and EF). This is inconsistent with
prior studies that have found deficits on these tasks secondary to loss of dopamine in the
striatum, which has direct connections to the frontal cortex (Kehagia, Barker, & Robbins,
2010; Kudlicka, Clare, & Hindle, 2011; Williams-Gray et al., 2013). One possible
explanation for this finding is that the majority of the PD patients in our sample were on
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dopaminergic medication. Administration of dopaminergic medication may replete
dopamine deficient circuits, thus in the early stages of the disease, may have a beneficial
effect on cognitive functions associated with the cortico-striato-thalamo-cortical loop
(e.g., EF) (Cools, 2006; Cools & D’Esposito, 2011; Poletti & Bonnucelli,
2013).

Therefore, it is presumed that the normalizing effects of dopaminergic

medications may have contributed to the overall lack of cognitive impairment findings
within the PD sample. Additional studies assessing PD patients off of their medication or
drug naive patients are warranted. Furthermore, the PD patients were in the early stages
of the disease (i.e., disease duration M= 4.8 years), which could have contributed to the
lack of neuropsychological deficits found in this sample. Our findings of no statistical
differences in cognition between PD and controls did converge with one study (Cropley
et al., 2008), however this study only utilized two neuropsychological measures to assess
cognition in their groups. Additionally, a recent study of PD patients without dementia (n
=143) found that significant caudate nucleus dopaminergic denervation was frequent in
those with minimal to no cognitive changes (51.1%) (Bohnen et al., 2015), therefore
illustrating that biochemical and structural change does not always result in cognitive
deficits or clinical symptoms.
4.3

Relationships between Dopamine and Cognition: PD
The present study demonstrated that DaT imaging correlates with certain

measures of cognitive functioning within a sample of PD patients. A strong positive
association was found between DaT availability in the left caudate and problem
solving/set-shifting.

This finding is in agreement with other studies that have

demonstrated significant associations between DaT availability in the caudate and set-
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shifting (Monchi et al., 2001; Rogers et al., 2000), as well as various other aspects of EF
in patients with PD (Chung et al., 2018; Muller, 2000; Nobili, 2010; Pollito, 2012;
Pellechia et al., 2015; Rinne, 2000; Siepel et al., 2014). Set-shifting is defined as the
ability to change our attention from one response set to another according to the changing
goals of a task (Provost, Hanganu, & Monchi, 2015). Secondly, there were significant
strong relationships between DaT in all striatal areas and verbal memory, such that
greater DaT availability was associated with better verbal memory.

This result is

consistent with findings from other studies that have found a significant relationship
between DaT availability in the caudate nucleus and verbal memory (Siepel et al., 2014)
and significant associations between FDOPA uptake in the caudate and both verbal and
visual memory (Jokinen et al., 2010). Memory deficits in PD patients without dementia
often stem from inefficient learning and organization due to frontostriatal dysfunction
(Adams, 2009; Getz & Levin, 2017). Patients with PD have also demonstrated difficulty
with free recall on memory tasks, but benefit from cues, suggesting that the memory
problems in PD are sometimes related to impaired executive functioning required for
memory retrieval (Getz & Levin, 2017). Thus, the memory findings in our sample may
be representing a dysexecutive process rather than a pure memory deficit, however due to
the use of a composite scores we could not examine retention scores explicitly.
Finally, our study found that DaT availability in the striatum was significantly
positively related to visuospatial functioning. This finding is consistent with a recent
study by Chung and colleagues (2018) who found that DaT availability in the caudate
was positively associated with visuospatial functioning in a large sample of PD patients
without dementia (n = 311). A similar finding was found in a sample of PD patients
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with MCI, in which reduced DaT availability in the caudate and putamen were associated
with lower scores on a visuospatial construction task (Pellechia et al., 2015).

Of note,

both studies used the Rey Complex Figure Copy to assess visuospatial functioning; thus,
the motor component involved in the task could have confounded their results. In
contrast, another large multicenter study consisting of patients from the PPMI, a cohort of
de novo PD patients, failed to find significant relationships between DaT binding and the
JOLO (Siepel et al., 2014). As observed with memory deficits, visuospatial deficits in
early PD may reflect executive deficits related to frontostriatal dysfunction, rather than a
pure visuospatial difficulty (Adams, 2009; Getz & Levin, 2017). Pure visuospatial
deficits may represent more posterior cortical dysfunction and can predict dementia (Getz
& Levin, 2017; Kehagia, Barker, & Robbins, 2010; Williams-Gray et al., 2013).
4.4

Relationships between Dopamine and Cognition: Controls
Similar relationships were found between DaT availability and cognition in age

and education matched controls.

Specifically, there were significant positive

relationships between DaT availability in the striatum and performance on measures of
verbal memory, inhibition, and problem solving/set-shifting. There are several potential
explanations for the amount of significant correlations in the control group. First, 12
subjects in the control group had a diagnosis of ET. ET is a non-neurodegenerative
disorder and is the most common cause of tremor.

ET results in an action or postural

tremor as opposed to the resting tremor associated with parkinsonism (Gunzler,
Schoenberg, Riley, Walter,& Maciuna; 2011). Although ET is typically associated with a
normal DaTscan, some studies have reported mild striatal dopaminergic deficit in patients
with ET compared to healthy controls, particularly in the caudate nucleus (Isais et al.,
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2010; Gerasimou et al., 2012; Waln et al., 2015). Furthermore, some studies have
reported neuropsychological deficits in patients with ET, particularly in the domains of
attention, working memory, and EF (Gasparini et al., 2001; Lombardi et al., 2001;
Troster et al., 2002), which can occur as a result of the cerebello-thalamo-cortical circuit
dysfunction that occurs with ET (Troster et al., 2002).
Additionally, there are other confounding variables that are inevitable when
assessing cognition within an older adult sample. The presence of cognitive impairment
increases with age, with EF abilities being among the first to decline (Aine et al., 2014;
Zelazo, Craik, & Booth, 2004). Furthermore, age-related changes in dopamine have also
been reported, albeit at a slower rate than patients with PD (Kassinen & Rinne, 2002;
Volkow et al., 1998) Specifically, the availability of D1-like (i.e., D1 and D5) dopamine
receptors in the striatum decrease at a rate ~7% per decade and D2-like (i.e., D2 ,D3, and
D4) receptors decrease between 5-10 % per decade in striatal availability (Kassinen &
Rinne, 2002). Of note, the DaTscans of all control participants in this study were
interpreted as having normal striatal uptake.
White matter hyperintensities (WMH) are a common finding in the brains of older
individuals, and are associated with vascular risk factors (e.g. hypertension, diabetes
mellitus, and cerebral amyloid angiopathy). These vascular risk factors have been
independently associated with cognitive decline of a frontal-subcortical nature initially,
affecting executive functioning and processing speed in particular (Adams, 2009; Aine et
al., 2014). Thus, the increased incidence of vascular risk factors that come with old age
may cause otherwise “normal” controls to look neuropsychologically similar to other
subcortical illnesses, such as PD. Due to limited sample sizes, we did not exclude
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patients with vascular risk factors, with the exception of major strokes and structural
lesions. As such, over half (n =14) of the participants in the control group had evidence
of cardiovascular disease according to medical record review (i.e., hypertension,
hyperlipidemia, and diabetes mellitus type 2), which may have confounded the results.
By including a control group consisting of patients with ET and older adults we are aware
of the suboptimal “healthy” control group. However, there are ethical considerations
when studying radioactive compounds in healthy subjects; as such, control participants in
neuroimaging studies are often bound by certain constraints.
Finally, low and/or abnormal neuropsychological test scores are common in
normative samples, with the frequency increasing with the more tests included in the
battery. Additional explanations for subtest scatter within a normative sample may also
include measurement error, longstanding weaknesses in certain domains of cognitive
functioning, and other situational factors (e.g., fluctuations in attention, motivation, or
effort, and fatigue) (Binder, Iverson, & Brooks, 2009)
4.5

Relationships between DaT and Affect
The present study found strong inverse associations between DaT availability in

the left striatum and putamen and motor impulsiveness, such that lower DaT levels were
associated with greater motor impulsiveness. Impulsivity is a heterogeneous construct
and can be broadly divided into decisional (e.g., reduced sensitivity to adverse outcomes
during learning and risk taking) and motor forms (e.g., impaired inhibition of a prepotent
response) (Voon et al., 2017). DaT imaging studies have consistently reported reduced
striatal DaT availability in patients with PD with ICD symptoms compared to those
without ICD symptoms (Smith, Xie, & Weintraub, 2016;Voon et al., 2010; Vriend et al.,
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2014). Small preliminary studies that have found associations between reduced striatal
DaT availability and increased ICD symptoms in both prevalent (Voon et al., 2014) and
incident (Vriend et al., 2014) ICD samples. A large study using data from the PPMI
database followed patients longitudinally to investigate neurobiological risk factors for
ICD symptoms. The sample included patients both on and off DRT. In patients on DRT,
a greater decrease in right caudate and mean striatal DaT over the first year was
significantly associated with an increased risk of incident ICD symptoms. In addition,
lower right putamen DaT availability at a given post-baseline visit was associated with
incident ICD symptoms at that visit in the DRT subgroup (Smith, Xie, & Weintraub,
2016).
This relationship between reduced DaT availability and ICD symptoms is not
entirely clear and several hypotheses have been suggested. One hypothesis is a more
pronounced dopaminergic denervation in patients with PD with ICD symptoms. The
DaT is the primary mechanism by which dopamine is removed from the synapse to
terminate its action.

The low DaT concentrations in patients with PD with ICD

symptoms could result in increased synaptic accumulation and therefore longer duration
of action for dopamine (Vriend et al., 2014). Additionally, having a genetic risk factor
for lower DaT availability or premorbid personality traits predisposing an individual to
ICD symptoms have also been proposed as possible explanations (Voon et al., 2017;
Vriend et al., 2014).
Executive functioning deficits have also been associated with ICD symptoms,
including impulsive decision making and impaired set-shifting (Voon et al., 2010).
Dopaminergic medications can have influence cognitive processes by enhancing learning
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from positive feedback, but impairing learning from negative feedback thereby increasing
impulsive behaviors.

ICD behaviors in PD tend to be under recognized, in part due to

the fact that screening is not common and patients may not report symptoms associated
with ICDs secondary to embarrassment or lack of awareness. DaT imaging may be a
useful tool in identifying predictive factors that may guide treatment decisions regarding
DRT use. Future studies should also examine the differential role of dopamine agonists
versus other DRT, as well as the relationship between DaT availability in the four major
ICDs independently (e.g., compulsive gambling, eating, buying, and sexual behavior).
4.6

Limitations
While the study provided an important contribution to the literature on the role of

striatal dopamine on cognitive and emotional functioning in patients with PD, limitations
must be acknowledged. First, the patient and control samples were both small and
varied, as is typical for SPECT imaging studies due to the use of radioactive compounds.
The study was also limited by low power which may have reduced the possibility of
finding significant correlations between biological and cognitive variables. Conversely,
the significant findings in small samples also raise the possibility of overestimation;
therefore, the p-values in this small sample should be interpreted with caution. A related
methodological concern is Type 1 error (i.e., rejecting the null hypothesis when the null
is true, a false positive) due to multiple comparisons. The current study did not involve a
correction (e.g. Bonferroni) for Type I error due to the exploratory nature of the analyses.
Further, given the limited sample size, the caution in relying on p-values in small
samples, and the risk of neglecting Type 2 error, preservation of power was a priority.
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Additionally, the present study utilized a cross-sectional design, thus significant
correlations suggest an association between variables but do not imply causation.
Most PD patients in this sample were on dopaminergic medication at the time of
their neuropsychological evaluation, which could have influenced the cognitive results by
potentially ameliorating deficits. Furthermore it is important to consider our findings in
the context of the broader scope of neuropathological mechanisms that contribute to
cognitive dysfunction in PD, beyond those of the striatal dopaminergic system. Cortical
and striatal beta-amyloid deposition, alpha-synuclein, genetic variation in the
microtubule-associated tau (MAPT) H1 haploptype, and the involvement of other
neurotransmitter

systems

(e.g., noradrenergic,

cholinergic,

serotonergic)

have

demonstrated a role in the cognitive deficits seen in PD, particularly in the later stages of
the disease (Cools, 2006; Halliday, Leverenz, Schneider & Adler, 2016; Kehagia, Barker,
& Robbins, 2010; Shah et al., 2016). For the purpose of this study, the neurochemical
focus was restricted to imaging the nigrostriatal dopamine system, thus our study could
not account for these other factors known to contribute to cognitive functioning in PD,
which we acknowledge as a limitation.

Future studies should examine the potential

interactions of these multiple pathological mechanisms in large samples to fully capture
the variety of neural underpinnings associated with cognitive functioning in
PD. Additional longitudinal studies that follow patients from the early un-medicated
stages to dementia are also warranted.
4.7

Conclusions
In sum, if cross-validated, the results of the present study suggest that striatal

dopamine is associated with performance in executive, verbal memory, and visuospatial
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functions in patients with PD. However, the literature suggests that the correlates of
these deficits to DaT availability likely depend on the neuropsychological tasks utilized
and the severity of the disease in the sample (e.g., early vs. advanced disease). As the
disease progresses and with advancing age, the risk of other biological systems and cooccurring pathology (e.g., senile plaques and neurofibrillary tangles, microvascular
disease, and cerebral amyloid angiopathy) increases. Clinically, it is important for health
care professionals to be aware and consider the multiple neurobiological bases of
cognitive impairment in PD. In particular, investigations of how deficits early in the
disease relate to later developments (e.g., dementia) will continue to be increasingly
important in order to inform disease-modifying therapies.
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